MEDIPEL
The computed 12-month bankruptcy probability of MEDIPEL is 0.1% (very low). The 2025 annual accounts show equity of €221k and a net result of €158k. Its solvency ranks better than 67% of 2200 sector peers (fiscal year 2025). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.
| Equity | €221k |
| Net result | €158k |
| Better than sector | 67% |
| Active | 2 yrs |
Exceptional profile, strong across almost every axis.
Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?
Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.
See plans →| Metric | This company | Sector median | Position in the sector |
|---|---|---|---|
| Solvency | 76.8% | 57.9% | |
| Net result | €158k | €60k | |
| Equity | €221k | €74k | |
| Gross operating margin | €214k | €96k | |
| Total assets | €288k | €186k |
| Fiscal year | 2025 |
|---|---|
| Revenue | - |
| EBITDA | €214k |
| Net profit | €158k |
| Cash flow | €164k |
| Staff costs | - |
| Income taxes | €48k |
| Dividends | €860 |
| Total assets | €288k |
| Equity | €221k |
| Debt | €67k |
| of which ≤ 1y | €66k |
| of which > 1y | - |
| Working capital | €190k |
| Employees (FTE) | - |
| 2025 | |
|---|---|
| Current ratio | 3.86 |
| Quick ratio | 3.86 |
| Working capital ratio | 66.2% |
| Solvency | 76.8% |
| Debt / equity | 0.30 |
| Long-term debt ratio | - |
| Interest coverage | 110.43 |
| Gross margin | - |
| Net margin | - |
| ROA | 54.8% |
| ROE | 71.4% |
| EBITDA margin | - |
| Days sales outstanding | - |
| Days payable outstanding | - |
| Inventory turnover | - |
| Days inventory (DSI) | - |
| Line item | Code | 2025 |
|---|---|---|
| Balance sheet, Assets | ||
| TOTAL ASSETS | 20/58 | €288k |
| Fixed assets | 21/28 | €28k |
| Formation expenses | 20 | €2k |
| Tangible fixed assets | 22/27 | €28k |
| Current assets | 29/58 | €257k |
| Cash & bank | 54/58 | €249k |
| Balance sheet, Equity & liabilities | ||
| TOTAL EQUITY & LIABILITIES | 10/49 | €288k |
| Equity | 10/15 | €221k |
| Contributions / capital | 10/11 | €2k |
| Reserves | 13 | €219k |
| Accumulated profits (losses) | 14 | €0 |
| Amounts payable | 17/49 | €67k |
| Amounts payable within one year | 42/48 | €66k |
| Trade debts payable within one year | 44 | €735 |
| Income statement | ||
| Gross operating margin | 9900 | €214k |
| Operating result | 9901 | €207k |
| Financial income | 75 | €129 |
| Financial charges | 65 | €2k |
| Result before taxes | 9903 | €205k |
| Income taxes | 67/77 | €48k |
| Net result for the period | 9904 | €158k |
| Result to be appropriated | 9905 | €158k |
| NACE primary | General medical practice(86210) |
| Legal form | Private limited company(610) |
| Incorporation | 26-10-2023 |
| Status | Active |
| Postal code | 9880 |
Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.
| Parcel (capakey) | Region | Area | Buildings | Height / fl. |
|---|---|---|---|---|
| 44035C0017/00P002 | Flanders | 990 m² | 1 · 306 m² | - |
| 44035C0019/00G000 | Flanders | 512 m² | 1 · 115 m² | 5.7 m · 1 fl. |
A single timeline of everything that happened to this company, publications, insolvency and lifecycle events, administrative changes and filed annual accounts.
Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.
| Legal nameNL | MEDIPEL |